Manufacturer "Longidase" is exploring its inhalation form

Petrovax Pharm is developing the inhalation form of its original drug Longidase. This was told in an interview with Kommersant by the president of the company Mikhail Tsyferov.

According to him, the new form of the drug has already passed the first phase of clinical trials. The manufacturer expects that inhaled Longidase will be effective in the treatment of interstitial lung diseases that cause damage to connective tissue.

Longidase is an enzyme drug with anti-inflammatory and anti-fibrous action, developed by Petrovax and launched on the market in 2005. The drug is used to treat and prevent the formation of scars and proliferation of connective tissue, is widely used in gynecology and urology.

Mikhail Tsyferov also spoke about the company’s plans to launch two major vaccine research projects in 2027.

More about how they are developed and how much innovation costs in the pharmaceutical industry, – in an interview with Mikhail Tsyferov “Kommersant”.

Victoria Kolganova